http://www.ncbi.nlm.nih.gov/pubmed/23460820

PLoS One. 2013;8(2):e56921. doi: 10.1371/journal.pone.0056921. Epub 2013 Feb 27.

The timing of drug funding announcements relative to elections: a case study involving dementia medications.

Gill SS, Gupta N, Bell CM, Rochon PA, Austin PC, Laupacis A.

Source

Department of Medicine, Queen's University, Kingston, Ontario, Canada ; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.

Abstract

BACKGROUND:

Following initial regulatory approval of prescription drugs, many factors may influence insurers and health systems when they decide whether to add these drugs to their formularies. The role of political pressures on drug funding announcements has received relatively little attention, and elections represent an especially powerful form of political pressure. We examined the temporal relationship between decisions to add one class of drugs to publicly funded formularies in Canada's ten provinces and elections in these jurisdictions.

METHODS:

Dates of provincial formulary listings for cholinesterase inhibitors, which are drugs used to treat Alzheimer's disease and related dementias, were compared to the dates of provincial elections. Medical journal articles, media reports, and proceedings from provincial legislatures were reviewed to assemble information on the chronology of events. We tested whether there was a statistically significant increase in the probability of drug funding announcements within the 60-day intervals preceding provincial elections.

RESULTS:

Decisions to fund the cholinesterase inhibitors were made over a nine-year span from 1999 to 2007 in the ten provinces. In four of ten provinces, the drugs were added to formularies in a time period closely preceding a provincial election ( = 0.032); funding announcements in these provinces were made between 2 and 47 days prior to elections. Statements made in provincial legislatures highlight the key role of political pressures in these funding announcements.

CONCLUSIONS:

Impending elections appeared to affect the timing of drug funding announcements in this case study. Despite an established structure for evidence-based decision-making, drug funding remains a complex process open to influence from many sources. Awareness of such influences is critical to maintain effective drug policy and public health decision-making.